Welcome - Debiopharm, We develop for patients

About us
Welcome
At a glance
Mission & Values
History
Let's meet
Debiopharm Group
Debiopharm International S.A.
Debiopharm Research & Manufacturing S.A.
Debiopharm Investment S.A.
Debiopharm Innovation Fund S.A.
GenePOC Inc.
Scientific Awards & Grants
Debiopharm Academy
Entrepreneurship
Social Responsibility
Contact Center
Our Headquarter is located in Lausanne/Switzerland.
Phone +41 (0)21 321 0111
To find the numbers of all the Debiopharm Group's companies, use this page.
Business
Business Model
Partnering
Pipeline
Translational Medicine
Drug Discovery & Preclinical
Clinical development
Innovative drug delivery and formulation
Manufacturing & Quality Assurance
Regulatory
Product Pipeline
More info
Products
Eloxatin® / Elplat® / Dacotin® / Dacplat®
Oxaliplatin is a diaminocyclohexane (DACH) platin for the treatment of colorectal cancer.
Decapeptyl® / Trelstar® / Pamorelin® / Neo Decapeptyl®/Triptodur®
1 to 6 month formulation for the treatment of prostate cancer, of endometriosis, precocious puberty, uterine fibroids, ovarian cancer, breast cancer, female infertility.
Salvacyl® / Moapar®
For the treatment of severe sexual deviations.
We develop for patients
More infos
Careers
Working at Debiopharm
Approximately 400 people of more than 18 nationalities from Europe, North and South America, Africa and Asia are employed at Debiopharm Group™ on its sites.
More info
Jobs
Senior Clinical Safety and Pharmacovigilance OfficerLausanne
Research Associate, 100%Martigny
Open positions Spontaneous application
Media
Press Releases
Events
Contact media relations
Publications
Logo & Media Download Area
Videos
Latest news
Increased Overall Survival (OS) of patients with pancreatic cancer: results of a Phase III study of adjuvant mFOLFIRINOX presented at ASCO 2018Debiopharm Group - 29 June 2018 All News
Debiopharm TV

Latest news

08 May 2018

International

FDA Grants Fast Track designation to Debiopharm International’s Debio 1347 for the treatment of patients with unresectable or metastatic tumors with a specific FGFR gene alteration

ALL NEWS

Debiopharm's vision of healthcare is not limited to making new medicines available. We strongly believe that you can be an actor in your own medical care. Your safety is our top priority.